Selective inhibition of leukotriene B4 formation by Ebselen: a novel approach to antiinflammatory therapy.
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology*; D001095:Arachidonic Acids / Q000096:biosynthesis / Q000378:metabolism; D001393:Azoles / Q000494:pharmacology*; D001792:Blood Platelets / Q000378:metabolism; D006801:Humans; D066298:In Vitro Techniques; D054833:Isoindoles; D007962:Leukocytes / Q000378:metabolism; D017572:Leukotriene A4; D007975:Leukotriene B4 / Q000096:biosynthesis*; D015289:Leukotrienes; D016566:Organoselenium Compounds; D012643:Selenium / Q000494:pharmacology*; D013552:Swine
D000893:Anti-Inflammatory Agents; D001095:Arachidonic Acids; D001393:Azoles; D054833:Isoindoles; D017572:Leukotriene A4; D015289:Leukotrienes; D016566:Organoselenium Compounds; D007975:Leukotriene B4; C042986:ebselen; C025348:arachidonic acid 5-hydroperoxide; D012643:Selenium